SAR of benzoylpyridines and benzophenones as p38α MAP kinase inhibitors with oral activity

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 13, 2004, Pages 3601-3605

  Revesz, Laszlo ^a   Blum, Ernst ^a   Di Padova, Franco E ^a   Buhl, Thomas ^a   Feifel, Roland ^a   Gram, Hermann ^a   Hiestand, Peter ^a   Manning, Ute ^a   Rucklin, Gerard ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BENZOPHENONE DERIVATIVE; BENZOYLPYRIDINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; NONHUMAN; RAT; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BENZOPHENONES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MOUTH; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2942560873     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.03.111     Document Type: Article

References (25)

1. Chakravarty S., Dugar S. Annu. Rep. Med. Chem. 37:2002;177-186
2. Jackson P.F., Bullington J.L. Curr. Topics Med. Chem. 2:2002;1011-1020
3. Cirillo P.F., Pargellis C., Regan J. Curr. Topics Med. Chem. 2:2002;1021-1035
4. Independently, Leo Pharma claimed benzophenones for topical use. Havez, S. E. WO 0283622, Chem. Abstr. 2002, 137, 325234; Horneman, A. M. WO 0190074, Chem. Abstr. 2002, 136, 579
5. Independently, Leo Pharma claimed benzophenones for topical use. Havez, S. E. WO 0283622, Chem. Abstr. 2002, 137, 325234; Horneman, A. M. WO 0190074, Chem. Abstr. 2002, 136, 5794
6. Yamamoto T., Ito T., Kubota K. Chem. Lett. 1:1988;153-154
7. Revesz, L. WO 0276447, Chem. Abstr. 2002, 137, 279216
8. Muci A.R., Buchwald S.L. Topics Curr. Chem. 219:2002;133-209
9. Bowden K., Heilbron I.M., Jones E.R.H., Weedon B.C.L. J. Chem. Soc. 1946;39-45
10. Sonogashira K., Tohda Y., Hagihara N. Tetrahedron Lett. 16:1975;4467-4470
11. Sonogashira K. Diederich F., Stang P.J. Metal-Catalyzed Cross-Coupling Reactions. 1998;Wiley-VCH, Weinheim. Chapter 5
12. Stille J.K. Angew. Chem., Int. Ed. Engl. 25:1986;508-524
13. Papadopoulos E.P., Jarrar A., Issidorides C.H. J. Org. Chem. 31:1966;615-616
14. A phosphorylated form of His-p38α MAP kinase (10 ng/well) of murine origin was used and immobilized GST-ATF-2 as substrate in the presence of 120 μM cold ATP
15. The proposed binding mode of benzoylpyridines and benzophenones to p38α implies, that the carbonyl oxygen forms a crucial H-bridge to the NH of Met109 and the difluorophenyl ring accommodates in the lipophilic binding pocket near Thr106. Reduction of the ketone to an alcohol or to a methylene group renders molecules inactive (data not shown)
16. Eight-week old female OF1 mice were dosed orally by gavage with solutions of the compounds in DMSO/cornoil. One hour after dosing, LPS (20 mg/kg) was injected iv for stimulation of TNFα release into plasma. One hour later blood was collected and TNFα was determined using a mouse specific ELISA
17. AIA: Adjuvant induced arthritis. Female Wistar rats were immunized with Mycobacterium tuberculosis at day 0 and dosed with the compounds twice (b.i.d.) 25 mg/kg po per day from day 14-20. Swelling of the joints was measured on day 20
18. 50 > 2 μM for human P450 isoenzymes CYP1A2, CYP2C9, CYP2D6, CYP3A4
19. 50 > 80 μM for COX-1
20. Profiling continued, if Ames assay and the Comet assay (in vitro with human lymphocytes) were negative
21. CIA: Collagen induced arthritis. Female (WAGxBUF/F1) rats were immunized intradermally with bovine nasal septum type II collagen emulsified in Freund's incomplete adjuvant. Swelling started ∼10 days after immunization. Dosing of compounds started on day 13, when swelling was nearly maximal. Compounds were dosed once (qd) daily for 10 days
22. Haddad J.J. Curr. Opin. Invest. Drugs. 2:2001;1070-1076
23. Regan J., Breitfelder S., Cirillo P., Gilmore T., Graham A.G., Hickey E., Klaus B., Madwed J., Moriak M., Moss N., Pargellis C., Pav S., Proto A., Swinamer A., Tong L., Torcellini C. J. Med. Chem. 45:2002;2994-3008
24. 50 or % inhibition at 10 μM for 10b/19b): JNK2 (>10 μM/; CDK1: (-32%/0%); HER-1 (8.8 μM/-10%); c-Abl (-36%/-15%); c-Src (-10%/0%); Kdr (-33%/-13%); c-Met (1.5 μM/-34%); FGFR (-16%/0%); c-Kit (-12%/0%); IGF1R (0%/0%); HER-2 (4.4 μM/-24%); Flt-3 (-11%/n.t.); c-Raf (0%/n.t.)
25. Revesz L., Di Padova F.E., Buhl T., Feifel R., Gram H., Hiestand P., Manning U., Wolf R., Zimmerlin A.G. Bioorg. Med. Chem. Lett. 12:2002;2109-2112